Clinical Trials Browser

Phase 2 × Inflammatory Breast Neoplasms × Doxorubicin × Clear all

Breast Neoplasms, Inflammatory Breast Neoplasms

NCT02876302 2026-02-04

Study Of Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast Cancer

Phase 2 Active not recruiting

23 enrolled 18 charts

Breast

Breast Neoplasms, Inflammatory Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02623972 2025-11-25

A Phase 2 Study of Eribulin Followed by AC as Preoperative Therapy for HER2-negative Inflammatory Breast Cancer

Phase 2 Active not recruiting

22 enrolled 12 charts

Breast

Inflammatory Breast Neoplasms

NCT00295893 2025-09-25

Combination Chemotherapy With or Without Trastuzumab in Treating Patients With Stage II or Stage III Breast Cancer

Phase 2 Active not recruiting

121 enrolled 10 charts

Breast

Breast Neoplasms, Carcinoma, Ductal, Breast, Carcinoma, Lobular, Breast Neoplasms, Male, Inflammatory Breast Neoplasms

NCT05177796 2024-10-24

Panitumumab and Pembrolizumab in Combination With Neoadjuvant Chemotherapy for the Treatment of Stage III-IV Triple Negative Breast Cancer

Phase 2 Withdrawn

Breast

Inflammatory Breast Neoplasms, Triple Negative Breast Neoplasms

NCT00513695 2019-08-07

Sunitinib Malate, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide Before Surgery in Treating Patients With Stage IIB-IIIC Breast Cancer

Phase 2 Completed

68 enrolled 10 charts

Breast

Breast Neoplasms, Breast Neoplasms, Male, Inflammatory Breast Neoplasms

NCT00499122 2018-01-02

NOV-002, Doxorubicin, Cyclophosphamide, and Docetaxel in Women With Newly Diagnosed Stage II or IIIC Breast Cancer

Phase 2 Completed

41 enrolled 10 charts

Breast

Breast Neoplasms, Inflammatory Breast Neoplasms

NCT00006110 2017-07-31

NRR

Phase 2 Completed

82 enrolled 13 charts

Breast

Breast Neoplasms, Inflammatory Breast Neoplasms

NCT00856492 2017-06-27

S0800, Nab-Paclitaxel, Doxorubicin, Cyclophosphamide, and Pegfilgrastim With or Without Bevacizumab in Treating Women With Inflammatory or Locally Advanced Breast Cancer

Phase 2 Completed

215 enrolled 13 charts

Breast

Breast Neoplasms, Inflammatory Breast Neoplasms

NCT00049114 2013-06-06

Tipifarnib, Doxorubicin, and Cyclophosphamide in Treating Women With Locally Advanced Breast Cancer

Phase 2 Completed

62 enrolled

Breast

Breast Neoplasms, Inflammatory Breast Neoplasms

NCT00005800 2012-09-25

Doxorubicin and Docetaxel in Treating Women With Stage III Breast Cancer

Phase 2 Completed

45 enrolled

Breast

Breast Neoplasms, Inflammatory Breast Neoplasms

Clinical Trials

Chemotherapy and Stem Cell Transplantation in Treating Patients With Stage IIIB Breast Cancer

Study Of Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast Cancer

A Phase 2 Study of Eribulin Followed by AC as Preoperative Therapy for HER2-negative Inflammatory Breast Cancer

Combination Chemotherapy With or Without Trastuzumab in Treating Patients With Stage II or Stage III Breast Cancer

Panitumumab and Pembrolizumab in Combination With Neoadjuvant Chemotherapy for the Treatment of Stage III-IV Triple Negative Breast Cancer

Sunitinib Malate, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide Before Surgery in Treating Patients With Stage IIB-IIIC Breast Cancer

NOV-002, Doxorubicin, Cyclophosphamide, and Docetaxel in Women With Newly Diagnosed Stage II or IIIC Breast Cancer

NRR

S0800, Nab-Paclitaxel, Doxorubicin, Cyclophosphamide, and Pegfilgrastim With or Without Bevacizumab in Treating Women With Inflammatory or Locally Advanced Breast Cancer

Tipifarnib, Doxorubicin, and Cyclophosphamide in Treating Women With Locally Advanced Breast Cancer

Doxorubicin and Docetaxel in Treating Women With Stage III Breast Cancer